Keywords: Eisia, Perampanel, NDA, USA, FDA, Gilead, Quad, HIV regimen
Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad
Article | 28 December 2011
Japanese drug major Eisai (TYO: 4523) says that it has re-submitted the New Drug Application (NDA) for the investigational AMPA-type glutamate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
